ANAB vs GPCR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ANAB · AnaptysBio$46.45 ▲ 1.91%
GPCR · Structure Therapeutics$20.35 ▲ 6.66%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ANAB +105.0%
- GPCR -40.0%
Head to head
| Metric | ANAB | GPCR |
|---|---|---|
| Price | $46.45 | $20.35 |
| Change today | ▲ 1.91% | ▲ 6.66% |
| Market cap | $1.39B | $1.45B |
| Return, 3 months | -16.3% | -62.2% |
| Return, year to date | +43.7% | -70.7% |
| Return, 1 year | +75.7% | -38.0% |
| P/E (TTM) | 8.3 | – |
| P/B | 131.2 | 1.1 |
| P/E percentile vs own 5y | 92nd | 94th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -8.0% | – |
| Net profit growth (YoY) | -34.5% | -72.2% |
| Gross margin | – | – |
| Operating margin | 17.6% | – |
| Net margin | -11.5% | – |
| Return on equity | -114.6% | -20.2% |
| Analyst target vs. price | +66.6% | +420.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 43 | 30 |
| 30-day volatility | 48.1% | 58.3% |
| Max drawdown, 1 year | -34.9% | -79.7% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GPCR is the largest of the group by market value.
- ANAB has returned the most over the past year.
- ANAB has been the calmest stock over the last 30 days.